Anbio Biotechnology
NNNN
12 hedge funds and large institutions have $985K invested in Anbio Biotechnology in 2026 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
50% more funds holding
Funds holding: 8 → 12 (+4)
0.05% more ownership
Funds ownership: 0.11% → 0.16% (+0.05%)
24% less capital invested
Capital invested by funds: $1.29M → $985K (-$305K)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$336K |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$288K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$35.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$24.4K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$1.93K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$138K |
| 2 |
Morgan Stanley
New York
|
-$2.68K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$2.57K |
| 4 |
EWA
EverSource Wealth Advisors
Birmingham,
Alabama
|
-$1.98K |
| 5 |
BTI
Blue Trust Inc
Alpharetta,
Georgia
|
-$128 |
NNNN Hedge Fund Activity: Q2 2026 in Review
12 of the 8,339 institutional investors tracked by Wall St. Rank reported a position in Anbio Biotechnology (NNNN) for Q2 2026, worth a combined $985K — down 24% from $1.29M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new NNNN positions and 2 closed out — a net gain of 4 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Bank of America, opening a new position worth an estimated $336K. The largest seller was UBS Group, cutting an estimated $138K.
- 12 institutional investors held Anbio Biotechnology (NNNN) as of Q2 2026, up from 8 in Q1 2026.
- Funds reported $985K of Anbio Biotechnology stock for Q2 2026, down 24% quarter-over-quarter.
- 6 funds opened new Anbio Biotechnology positions in Q2 2026 and 2 closed out, a net change of +4 holders.
- The largest Anbio Biotechnology buyer in Q2 2026 was Bank of America, an estimated $336K added.
- The largest Anbio Biotechnology seller in Q2 2026 was UBS Group, an estimated $138K sold.
Based on aggregated 13F filings for Q2 2026.